About Nexus Biosys
Focused on Biopharmaceutical Development
Biopharmaceutical Platform & Program Focus
Nexus Biosys is presented within the Apimeds Pharmaceuticals US corporate platform as a biopharmaceutical business focused on the Apitox development program.
Nexus Biosys (operates under Apimeds Pharmaceuticals US, Inc). The company supports clinical development strategies, regulatory preparations, and program evaluation for Apitox in knee osteoarthritis.
Apimeds Pharmaceuticals US, Inc. is listed on NYSE American under the trading symbol APUS.
Important Corporate Clarification
Nexus Biosys is not separately listed on a stock exchange. References to NYSE American and the symbol APUS relate exclusively to Apimeds Pharmaceuticals US, Inc.
Investigational Product Status
Apitox is an investigational product in the United States. It has not been approved by the U.S. Food and Drug Administration. Its safety and effectiveness have not been established for commercial use in the United States.
Apimeds Pharmaceuticals US, Inc.
Parent company listing details, corporate headquarters and investor channels.
Matawan, New Jersey 07747, USA